Variant:
chr17:41209080 in BRCA1 (VIP)

VIP Variant in BRCA1

The BRCA1 5382insC (5385insC) mutation is estimated to have arisen about 760 years ago [Article:8571953]. This mutation is one of the most common mutations identified among Ashkenazi Jewish families with a history of breast and/or ovarian cancer. The frequency of the mutation in the general Ashkenazi population, unselected for personal or family history of breast or ovarian cancer, is 0.25% or less (see table below).

Ashkenazi Population Number of Individuals Tested Number of Individuals with 5382insC* Percent PubMed ID
Israel3990 0.00 [Article:8841191]
U.S./Israel43300.00[Article:7550349]
United States271740.15 [Article:8841191]
Australia120030.25[Article:11466700]
Total474970.15

*These individuals may be heterozygotic or homozygotic for the 5382insC allele.

In high-risk Ashkenazi families with a history of breast and/or ovarian cancer, the frequency of the 5382insC mutation is significantly higher than in the general Ashkenazi population. In studies of high-risk families with breast and/or ovarian cancer, the percentage of Ashkenazi individuals with 5382insC mutations ranged from 6.5% to 9% [Articles:9042929, 9333265]. In another study, 9% of high-risk Jewish families with breast and/or ovarian cancer were found to harbor the 5382insC mutation, while this mutation was detected in 16% of the subset of families with both breast and ovarian cancer [Article:8898735].

The incidence of the 5382insC mutation in general or non-Jewish populations at high-risk for breast and/or ovarian cancer appears to be lower than that seen for the Ashkenazi population, in the range of 1-4% [Articles:9150149, 7837387, 8533757, 11896095, 7611277]. However, one report indicated 13% of high-risk families studied possessed the 5382insC mutation [Article:7894492].

Note that this variant is referred to in the literature as both 5382insC and 5385insC. The naming confusion is a result of the fact that the sequence from nucleotides 5383-5385 is 'CCC', so that it is impossible to tell at precisely which location the additional C is being inserted.

Please Note: The BRCA1 gene is found on the minus chromosomal strand. Please note that for standardization, the PharmGKB presents all allele base pairs on the positive chromosomal strand, therefore the alleles within our variant annotations will differ (in a complementary manner) from those in this VIP summary that are given on the minus strand as reported in the literature.

Key Publications:
Diseases Breast Neoplasms 1 2 3 4 5 6 7 8 9 10 Ovarian Neoplasms 11 12 13 14 15 16 17 18 19 20

Appendix

Genomic Variant & GenBank ID: 38462606 C > CC on NC_000017.9
HGVS Nomenclature: NC_000017.9:g.38462606dupC
mRNA Variant & GenBank ID: 5385 C > CC on U14680
HGVS Nomenclature: U14680:r.5385dupC
Protein Variant & GenBank ID: This insertion causes a frameshift that results in premature termination of the protein at codon 1829 [Article:7894492].
GoldenPath Position: Chr17: 38462606 (hg18)
DNA Source Containing Homozygous Minor Allele(Coriell Lines): White (Caucasian): GM13715/NA13715
Key Haplotypes: See BRCA1 Haplotype Information

Connected Diseases

Publications related to chr17:41209080: 13

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2002. Frank Thomas S, et al. [Article:11896095@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The frequency of founder mutations in the BRCA1, BRCA2, and APC genes in Australian Ashkenazi Jews: implications for the generality of U.S. population data. Cancer. 2001. Bahar A Y, et al. [Article:11466700@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
BRCA1 sequence variations in 160 individuals referred to a breast/ovarian family cancer clinic. Institut Curie Breast Cancer Group. American journal of human genetics. 1997. Stoppa-Lyonnet D, et al. [Article:9150149@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Transmission-disequilibrium tests for quantitative traits. American journal of human genetics. 1997. Allison D B. [Article:9042929@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
BRCA1 sequence analysis in women at high risk for susceptibility mutations. Risk factor analysis and implications for genetic testing. JAMA : the journal of the American Medical Association. 1997. Shattuck-Eidens D, et al. [Article:9333265@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Haplotype and phenotype analysis of six recurrent BRCA1 mutations in 61 families: results of an international study. American journal of human genetics. 1996. Neuhausen S L, et al. [Article:8571953@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Ashkenazi Jewish population frequencies for common mutations in BRCA1 and BRCA2. Nature genetics. 1996. Roa B B, et al. [Article:8841191@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Frequency of recurrent BRCA1 and BRCA2 mutations in Ashkenazi Jewish breast cancer families. Nature medicine. 1996. Tonin P, et al. [Article:8898735@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Detection of eight BRCA1 mutations in 10 breast/ovarian cancer families, including 1 family with male breast cancer. American journal of human genetics. 1995. Struewing J P, et al. [Article:7611277@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families. American journal of human genetics. 1995. Friedman L S, et al. [Article:8533757@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
A collaborative survey of 80 mutations in the BRCA1 breast and ovarian cancer susceptibility gene. Implications for presymptomatic testing and screening. JAMA : the journal of the American Medical Association. 1995. Shattuck-Eidens D, et al. [Article:7837387@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
The carrier frequency of the BRCA1 185delAG mutation is approximately 1 percent in Ashkenazi Jewish individuals. Nature genetics. 1995. Struewing J P, et al. [Article:7550349@PubMed]
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nature genetics. 1994. Simard J, et al. [Article:7894492@PubMed]

Cross-References

Common Searches

PharmGKB® is a registered trademark of HHS and is financially supported by NIH/NIGMS. It is managed at Stanford University (R24 GM61374).
©2001-2012 PharmGKB.